Independent · non-commercial · publishes on a quarterly cycle|Current cycle 2026 Q3
Methodology|Interests|Funding|Corrections
Compound Evidence InstituteEvidence synthesis · established 2023Graded assessments of compounds, trials, methods and supply
Document set current to 30 July 2026
Trial register facet

Reported trial records — page 5

644 records with the status reported.

Showing 0 records on this page

Records

644 documents · page 5 of 27

Table 1. Trial records on this page. The table sorts on any column and filters on the controls above; both operate on the records shown on this page only.

RecordCompoundPhaseStatusDesignRandomisedYearCertainty
SYNERGY-NASH-QOLprogramme recordTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
PETRE-PH1B-BIOMARKERprogramme recordPetrelintidePhase 1ReportedRandomised, double-blind, placebo-controlled—2024Very low
REIMAGINE-1-PKprogramme recordAmycretinPhase 1ReportedPhase 1 ascending dose—2024Very low
FLOW-HEPATIC-IMPprogramme recordSemaglutidePhase 1ReportedPhase 1 ascending dose—2024Very low
SUMMIT-OLEprogramme recordTirzepatidePhase 3ReportedSingle-arm open-label—2024Very low
SURVO-PH2-OBESITY-ADHERENCEprogramme recordSurvodutidePhase 2ReportedObservational—2024Very low
SYNERGY-NASH-BODY-COMPprogramme recordTirzepatidePhase 2ReportedRandomised, double-blind, placebo-controlled—2024Very low
PETRE-PH1B-ELDERLYprogramme recordPetrelintidePhase 1ReportedRandomised, double-blind, placebo-controlled—2024Very low
REIMAGINE-1-DDIprogramme recordAmycretinPhase 1ReportedRandomised crossover—2024Very low
SUMMIT-ELDERLYprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
MARITIDE-PH2-T2D-REGIONAL-CNprogramme recordMaridebart cafraglutidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SURMOUNT-4-REGIONAL-CNprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
SUMMIT-REGIONAL-JPprogramme recordTirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled—2024Very low
PETRE-PH1B-PKprogramme recordPetrelintidePhase 1ReportedPhase 1 ascending dose—2024Very low
STEP-HFpEFSemaglutidePhase 3ReportedRandomised, double-blind, placebo-controlled5292023Moderate
SELECTSemaglutidePhase 3ReportedEvent-driven cardiovascular outcome trial17,6042023High
OASIS-1Semaglutide, oralPhase 3ReportedRandomised, double-blind, placebo-controlled6672023Moderate
SURMOUNT-2TirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled9382023High
SURMOUNT-3TirzepatidePhase 3ReportedRandomised, double-blind, placebo-controlled8062023High
RETA-PH2-OBESITYRetatrutidePhase 2ReportedRandomised, double-blind, placebo-controlled3382023Moderate
RETA-PH2-T2DRetatrutidePhase 2ReportedRandomised, double-blind, placebo-controlled2812023Moderate
ORFO-PH2-OBESITYOrforglipronPhase 2ReportedRandomised, double-blind, placebo-controlled2722023Moderate
ORFO-PH2-T2DOrforglipronPhase 2ReportedRandomised, double-blind, placebo-controlled3832023Moderate
CAGRI-SEMA-PH2-T2DCagriSema (cagrilintide with semaglutide)Phase 2ReportedRandomised, double-blind, active-controlled922023Low

page 5 of 27

Nothing published by the Institute is medical advice, a diagnosis, a prescription, a treatment recommendation or a purchasing recommendation. Compounds supplied for research use are not approved for human or veterinary use in any jurisdiction, and a favourable analytical assessment of a supplier is not a statement that any product is safe or effective. The Institute publishes certainty ratings and never recommendations. No telephone number, messaging handle or ordering channel appears anywhere on this site.